KBC Group NV Trims Stake in Stryker Corporation $SYK

KBC Group NV lowered its position in Stryker Corporation (NYSE:SYK) by 14.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 265,410 shares of the medical technology company’s stock after selling 45,453 shares during the period. KBC Group NV’s holdings in Stryker were worth $83,562,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Godfrey Financial Associates Inc. bought a new position in Stryker in the 4th quarter worth about $26,000. Sankala Group LLC bought a new stake in shares of Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker during the fourth quarter worth about $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker in the fourth quarter worth approximately $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SYK. Truist Financial lifted their target price on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Leerink Partners lowered their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Evercore set a $350.00 price objective on shares of Stryker in a report on Monday, July 6th. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, UBS Group assumed coverage on Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Price Performance

Shares of NYSE:SYK opened at $338.80 on Friday. The stock has a market cap of $129.95 billion, a PE ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The company’s fifty day moving average is $324.61 and its 200 day moving average is $333.57. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the prior year, the business posted $3.13 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio is currently 36.48%.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.60% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.